ICT01
Acute Myeloid Leukemia (AML) & other cancers
Phase 1/2Active
Key Facts
Indication
Acute Myeloid Leukemia (AML) & other cancers
Phase
Phase 1/2
Status
Active
Company
About ImCheck Therapeutics
ImCheck Therapeutics is a clinical-stage biotech company developing novel immunotherapies targeting the butyrophilin (BTN) and BTN-like (BTNL) family of immune checkpoints, with a lead program (ICT01) in oncology. Founded in 2015 and based in Marseille, France, the company was recently acquired by Ipsen, a global biopharmaceutical company, in a move that validates its platform and provides significant resources for development. ImCheck's approach aims to activate gamma-delta T cells, a distinct subset of immune cells with potent anti-tumor activity, representing a differentiated strategy in the immuno-oncology landscape.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) & other cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| INB-300 / INB-330 | IN8bio | Preclinical |
| Undisclosed Platform Program | Yellowstone Biosciences | Preclinical |
| SCO-101 | Scandion Oncology | Pre-clinical |